Franck Grimaud - Valneva SE CEO
| AYJ Stock | EUR 1.97 0.03 1.50% |
CEO
Mr. Franck Grimaud was Chief Executive Officer, Member of the Management Board, Member of the Executive Committee of VALNEVA SE since May 10, 2013. He was Member of the Management Board, CoPresident and Chief Business Officer of Valneva SE as of the Company merger in 2012. Previously he was the Chairman of the Management Board and the Executive Committee of Vivalis SA from November 29, 2002 to 2012. He holds a Master in Business Administration from Ottawa University, and started his career as an organization and management consultant. He then joined Groupe Grimaud as Head of Development for Asia and then became Head of Development of the Veterinary Vaccines Division before creating Vivalis. He was also appointed Vice Chairman of the Atlantic Biotherapies business cluster and his present and former positions include Chief Executive Officer of Smol Therapeutics SAS, President and Representative Director of Vivalis Toyama Japan KK, and Director of Grimaud Deyang Animal Co Ltd and Chengdu Grimaud Breeding Co Ltd. since 2019.
| Age | 51 |
| Tenure | 5 years |
| Phone | 33 2 28 07 37 10 |
| Web | https://valneva.com |
Valneva SE Management Efficiency
The company has return on total asset (ROA) of (0.185) % which means that it has lost $0.185 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8614) %, meaning that it generated substantial loss on money invested by shareholders. Valneva SE's management efficiency ratios could be used to measure how well Valneva SE manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CEO Age | ||
| Z Chen | Origin Agritech | 49 | |
| Anders Storm | SIVERS SEMICONDUCTORS AB | 50 | |
Management Performance
| Return On Equity | -1.86 | |||
| Return On Asset | -0.18 |
Valneva SE Leadership Team
Elected by the shareholders, the Valneva SE's board of directors comprises two types of representatives: Valneva SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valneva. The board's role is to monitor Valneva SE's management team and ensure that shareholders' interests are well served. Valneva SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valneva SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic Jacotot, Vice President, General Counsel, Member of the Management Board, Member of the Executive Committee , General Secretary | ||
| AnneMarie Graffin, Independent Member of the Supervisory Board | ||
| Johanna Pattenier, Member of the Supervisory Board | ||
| Thomas Lingelbach, Chairman of the Management Board, President, Chief Executive Officer, Member of the Management Board | ||
| Louisa ShawMarotto, Vice Chairman of the Supervisory Board, Independent Director | ||
| Gerald Strohmaier, VP Resource | ||
| Frances Muir, Site Director Livingston, Member of the Executive Committee | ||
| Peter Buhler, CFO Member | ||
| Wolfgang Bender, Chief Medical Officer, Member of the Management Board, Member of the Executive Committee | ||
| Joshua Drumm, VP Relations | ||
| Dipal Patel, Chief Board | ||
| Franck Grimaud, Chief Executive Officer, Member of the Management Board, Member of the Executive Committee | ||
| Janet Hoogstraate, Chair of the Management Board of Valneva Sweden AB, Member of the Executive Committee | ||
| James Sulat, Independent Vice Chairman of the Supervisory Board | ||
| Franck MBA, Chief Gen | ||
| Frederic Grimaud, Chairman of the Supervisory Board | ||
| Juan Jaramillo, Chief Medical Officer, Member of the Management Board | ||
| David Lawrence, Chief Financial Officer, Member of the Management Board | ||
| Klaus Schwamborn, Vice President - Discovery Research & Innovation, Member of the Executive Committee | ||
| JuanCarlos MD, Chief Board | ||
| Michael Moehlen, Vice President Corporate Technical Development, Member of the Executive Committee | ||
| Andreas Meinke, Vice President Pre-clinical & Translational Research, Member of the Executive Committee | ||
| Perry Celentano, Interim Chief Operating Officer | ||
| Olivier Jankowitsch, Vice President Global Supply Operations, Member of the Executive Committee | ||
| Laetitia BachelotFontaine, Investor Relations Manager | ||
| Manfred Tiefenbacher, Vice President - Finance, Member of the Executive Committee | ||
| Thomas Casdagli, Member of the Supervisory Board - Representative of MVM Partners LLP | ||
| Jason Golan, Vice President Commercial Operations, Member of the Executive Committee | ||
| Sharon Tetlow, Member of the Supervisory Board |
Valneva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Valneva SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.86 | |||
| Return On Asset | -0.18 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 835.16 M | |||
| Shares Outstanding | 138.22 M | |||
| Shares Owned By Insiders | 17.56 % | |||
| Shares Owned By Institutions | 21.62 % | |||
| Price To Earning | 65.30 X | |||
| Price To Book | 5.70 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Valneva Stock
Valneva SE financial ratios help investors to determine whether Valneva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Valneva with respect to the benefits of owning Valneva SE security.